The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Diamond-Blackfan Anemia

Pure red cell aplasia in infants from ribosomal protein mutations responding to corticosteroids, transfusion, and allogeneic stem cell transplant

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Diamond-Blackfan Anemia?

Diamond-Blackfan anemia — inherited (mostly autosomal dominant, some sporadic) pure red cell aplasia with reticulocytopenia and decreased erythroid precursors in marrow; estimated incidence 5-7 per million live births; diagnosis typically by age 12 months with 90% by age 1 year.

Molecular pathogenesis — mutations in ribosomal protein genes (ribosomopathy) affecting 60-65% of patients: RPS19 (25%), RPL5, RPL11, RPS26, RPS24, RPL35A, others; GATA1 X-linked form; mechanism involves impaired ribosomal biogenesis with p53-mediated apoptosis of erythroid progenitors.

Clinical features — severe macrocytic anemia with reticulocytopenia, typically presenting 2-6 months of age; congenital anomalies in 40-50% (craniofacial: flat nasal bridge, wide-set eyes, small low-set ears; thumb abnormalities: triphalangeal, duplicated, absent; short stature; cardiac and GU anomalies); cancer predisposition (MDS, AML, osteosarcoma, colon cancer).

Treatment paradigm — corticosteroids (prednisolone 2 mg/kg/day initial) with 50-80% responding; chronic transfusion with iron chelation for non-responders; allogeneic HSCT curative with 85-90% success in matched sibling donors, lower with alternative donors; supportive care and genetic counseling; emerging gene therapy trials.

Symptoms

Severe pallor and fatigue in infant 2-6 months
Poor feeding and failure to thrive
Macrocytic anemia (high MCV for age) with reticulocytopenia
Craniofacial anomalies — triangular face, flat nasal bridge, widely set eyes
Thumb abnormalities — triphalangeal, duplicated, or absent/hypoplastic thumb
Short stature (60%), growth delay, short/webbed neck

Risk Factors

Family history of Diamond-Blackfan anemia (autosomal dominant)
Sporadic mutations (about 50% of cases, de novo)
Ribosomal protein gene mutations (RPS19, RPL5, RPL11, and others)
GATA1 mutation (X-linked form)
Consanguinity in recessive variants (rare)
Associated cancer risk — MDS, AML, osteosarcoma, colon cancer

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Infant with severe macrocytic anemia and reticulocytopenia, especially with thumb anomalies, craniofacial features, or short stature, warrants urgent pediatric hematology referral for bone marrow examination and genetic testing.
  • Known Diamond-Blackfan patient with escape from corticosteroid response, iron overload complications, or signs of MDS/AML requires prompt hematology evaluation with bone marrow reassessment.
  • Family history of Diamond-Blackfan warrants genetic counseling, prenatal testing options, and early hematologic evaluation of infants.

Treatment Methods

01
Diagnostic workup — CBC (macrocytic anemia with reticulocytopenia), bone marrow aspirate and biopsy (erythroid hypoplasia with normal myeloid/megakaryocyte lineages), erythrocyte adenosine deaminase (eADA) elevated (80%), fetal hemoglobin elevated, genetic testing panel for ribosomal protein genes, parental testing and genetic counseling.
02
Corticosteroid therapy — prednisolone 2 mg/kg/day initial for 2-4 weeks; responders (reticulocytosis, rising hemoglobin) taper slowly to lowest effective dose; steroid-dependent (50-80%) maintained long-term; non-responders transition to transfusion; monitor for side effects (growth suppression, bone health, adrenal suppression).
03
Transfusion therapy — chronic RBC transfusion every 3-4 weeks for non-responders or during steroid tapering; phenotypically matched blood; leukoreduced and irradiated products; target pretransfusion Hb 9-10 g/dL; monitor iron overload with ferritin, MRI T2* cardiac and T2 liver.
04
Iron chelation — initiate when ferritin >1000 ng/mL or after 20 transfusions; deferasirox (oral) first-line; deferiprone or deferoxamine alternatives; cardiac iron MRI monitoring; transfusion and chelation essential for long-term organ protection.
05
Hematopoietic stem cell transplantation — only curative therapy; matched sibling donor preferred with 85-90% survival in pediatric patients; matched unrelated donor 70-85%; outcomes better before severe iron overload; myeloablative or reduced-intensity conditioning; high-risk patients with MDS/AML transformation or refractory disease benefit most.
06
Long-term management and surveillance — cancer screening (MDS/AML annual bone marrow, osteosarcoma imaging, colon cancer screening from age 20-30), endocrine evaluation (growth, puberty, thyroid), bone density, cardiac function, fertility counseling; multidisciplinary care and transition to adult services; emerging clinical trials with lenalidomide, sotatercept, gene therapy.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.